{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:12:31Z","timestamp":1775041951865,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Guangdong S&T Program","award":["2023B1111030006"],"award-info":[{"award-number":["2023B1111030006"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372766"],"award-info":[{"award-number":["82372766"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangzhou Key Laboratory of Organ Transplantation","award":["2025A03J4036"],"award-info":[{"award-number":["2025A03J4036"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04711-z","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:55:45Z","timestamp":1772193345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["M2 macrophage related genes predict prognosis and drug response in prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Zhikai","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuohang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhou","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanyi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kewei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"10437","key":"4711_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683\u2013722.","journal-title":"Lancet"},{"issue":"2","key":"4711_CR2","doi-asserted-by":"publisher","first-page":"2279235","DOI":"10.1080\/07853890.2023.2279235","volume":"55","author":"Q Ge","year":"2023","unstructured":"Ge Q, Li J, Yang F, Tian X, Zhang M, Hao Z, et al. Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy. ANN MED. 2023;55(2):2279235.","journal-title":"ANN MED"},{"issue":"16","key":"4711_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMe2309502","volume":"389","author":"A Aparicio","year":"2023","unstructured":"Aparicio A. Biochemical Recurrence in Prostate Cancer - Tilting the Scale. NEW ENGL J MED. 2023;389(16):1522\u20133.","journal-title":"NEW ENGL J MED"},{"issue":"8","key":"4711_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s00259-023-06195-3","volume":"50","author":"S Spohn","year":"2023","unstructured":"Spohn S, Schmidt-Hegemann NS, Ruf J, Mix M, Benndorf M, Bamberg F, et al. Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy. EUR J NUCL MED MOL I. 2023;50(8):2537\u201347.","journal-title":"EUR J NUCL MED MOL I"},{"key":"4711_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s43856-022-00126-3","volume":"2","author":"H Pinckaers","year":"2022","unstructured":"Pinckaers H, van Ipenburg J, Melamed J, De Marzo A, Platz EA, van Ginneken B, et al. Predicting biochemical recurrence of prostate cancer with artificial intelligence. Commun Med (Lond). 2022;2:64.","journal-title":"Commun Med (Lond)"},{"key":"4711_CR6","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. PHARMACOL THERAPEUT. 2021;221:107753.","journal-title":"PHARMACOL THERAPEUT"},{"issue":"1","key":"4711_CR7","doi-asserted-by":"publisher","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","volume":"15","author":"A Kiviaho","year":"2024","unstructured":"Kiviaho A, Eerola SK, Kallio HML, Andersen MK, Hoikka M, Tiihonen AM, et al. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. NAT COMMUN. 2024;15(1):9949.","journal-title":"NAT COMMUN"},{"issue":"7989","key":"4711_CR8","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","volume":"623","author":"C Guo","year":"2023","unstructured":"Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature. 2023;623(7989):1053\u201361.","journal-title":"Nature"},{"key":"4711_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","volume":"530","author":"J Kang","year":"2022","unstructured":"Kang J, La Manna F, Bonollo F, Sampson N, Alberts IL, Mingels C, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. CANCER LETT. 2022;530:156\u201369.","journal-title":"CANCER LETT"},{"key":"4711_CR10","doi-asserted-by":"publisher","first-page":"888713","DOI":"10.3389\/fimmu.2022.888713","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao J, Liang Y, Wang L. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. FRONT IMMUNOL. 2022;13:888713.","journal-title":"FRONT IMMUNOL"},{"issue":"1","key":"4711_CR11","doi-asserted-by":"publisher","first-page":"2398195","DOI":"10.1080\/07853890.2024.2398195","volume":"56","author":"Y Ou","year":"2024","unstructured":"Ou Y, Xia C, Ye C, Liu M, Jiang H, Zhu Y, et al. Comprehensive scRNA-seq analysis to identify new markers of M2 macrophages for predicting the prognosis of prostate cancer. ANN MED. 2024;56(1):2398195.","journal-title":"ANN MED"},{"issue":"3","key":"4711_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00262-024-03633-5","volume":"73","author":"Z Kang","year":"2024","unstructured":"Kang Z, Zhao Y, Qiu RSQ, Chen D, Zheng Q, Xue X, et al. Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning. Cancer Immunol immunotherapy: CII. 2024;73(3):41.","journal-title":"Cancer Immunol immunotherapy: CII"},{"issue":"4","key":"4711_CR13","doi-asserted-by":"publisher","first-page":"e006020","DOI":"10.1136\/jitc-2022-006020","volume":"11","author":"S Chen","year":"2023","unstructured":"Chen S, Lu K, Hou Y, You Z, Shu C, Wei X, et al. YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. J IMMUNOTHER CANCER. 2023;11(4):e006020.","journal-title":"J IMMUNOTHER CANCER"},{"key":"4711_CR14","doi-asserted-by":"crossref","unstructured":"Gu Q, Qi A, Wang N, Zhou Z, Zhou X. Macrophage dynamics in prostate cancer: Molecular to therapeutic insights. Volume 177. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie; 2024. p. 117002.","DOI":"10.1016\/j.biopha.2024.117002"},{"issue":"6","key":"4711_CR15","doi-asserted-by":"publisher","first-page":"e004400","DOI":"10.1136\/jitc-2021-004400","volume":"10","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, et al. PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163\u2009+\u2009M2 macrophages. J IMMUNOTHER CANCER. 2022;10(6):e004400.","journal-title":"J IMMUNOTHER CANCER"},{"issue":"3","key":"4711_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7150\/thno.92336","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhao F, Lin Y, Liu M, Zhou H, Cui F, et al. Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression. THERANOSTICS. 2024;14(3):1065\u201380.","journal-title":"THERANOSTICS"},{"key":"4711_CR17","doi-asserted-by":"crossref","unstructured":"Bian X, Wang W, Abudurexiti M, Zhang X, Ma W, Shi G et al. Integration Analysis of Single-Cell Multi-Omics Reveals Prostate Cancer Heterogeneity. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024; 11(18):e2305724.","DOI":"10.1002\/advs.202305724"},{"issue":"1","key":"4711_CR18","first-page":"90","volume":"37","author":"T Ding","year":"2025","unstructured":"Ding T, He L, Lin G, Xu L, Zhu Y, Wang X, et al. Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer. Chin J cancer Res = Chung-kuo yen cheng yen chiu. 2025;37(1):90\u2013114.","journal-title":"Chin J cancer Res = Chung-kuo yen cheng yen chiu"},{"key":"4711_CR19","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England: 1990). 2009; 45(2):228\u2013247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"4711_CR20","doi-asserted-by":"publisher","first-page":"173090","DOI":"10.1016\/j.ejphar.2020.173090","volume":"877","author":"C Yunna","year":"2020","unstructured":"Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1\/M2 polarization. EUR J PHARMACOL. 2020;877:173090.","journal-title":"EUR J PHARMACOL"},{"issue":"1","key":"4711_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","volume":"16","author":"M Li","year":"2023","unstructured":"Li M, Yang Y, Xiong L, Jiang P, Wang J, Li C. Metabolism, metabolites, and macrophages in cancer. J HEMATOL ONCOL. 2023;16(1):80.","journal-title":"J HEMATOL ONCOL"},{"issue":"1","key":"4711_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12964-020-00557-2","volume":"18","author":"Q Liu","year":"2020","unstructured":"Liu Q, Yang C, Wang S, Shi D, Wei C, Song J, et al. Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression. CELL COMMUN SIGNAL. 2020;18(1):51.","journal-title":"CELL COMMUN SIGNAL"},{"issue":"37","key":"4711_CR23","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41388-023-02781-9","volume":"42","author":"S Chen","year":"2023","unstructured":"Chen S, Wang M, Lu T, Liu Y, Hong W, He X, et al. JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3\/IL-10 axis. Oncogene. 2023;42(37):2737\u201350.","journal-title":"Oncogene"},{"issue":"18","key":"4711_CR24","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1158\/0008-5472.CAN-22-0507","volume":"82","author":"D Li","year":"2022","unstructured":"Li D, Zhang Q, Li L, Chen K, Yang J, Dixit D, et al. beta2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages. CANCER RES. 2022;82(18):3321\u201334.","journal-title":"CANCER RES"},{"issue":"1","key":"4711_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-022-02477-0","volume":"41","author":"L Wang","year":"2022","unstructured":"Wang L, Li S, Luo H, Lu Q, Yu S. PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K\/AKT signaling in tumor cells and phenotypic polarization of macrophages. J EXP CLIN CANC RES. 2022;41(1):303.","journal-title":"J EXP CLIN CANC RES"},{"issue":"3","key":"4711_CR26","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/jcb.27681","volume":"120","author":"M Najafi","year":"2019","unstructured":"Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J CELL BIOCHEM. 2019;120(3):2782\u201390.","journal-title":"J CELL BIOCHEM"},{"issue":"2","key":"4711_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3724\/abbs.2024006","volume":"56","author":"H Yuan","year":"2024","unstructured":"Yuan H, Fang R, Fu C, Wang S, Tong X, Feng D, et al. ATIP\/ATIP1 regulates prostate cancer metastasis through mitochondrial dynamic-dependent signaling. ACTA BIOCH BIOPH SIN. 2024;56(2):304\u201314.","journal-title":"ACTA BIOCH BIOPH SIN"},{"issue":"10","key":"4711_CR28","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.4049\/jimmunol.0802797","volume":"182","author":"M Suzuki","year":"2009","unstructured":"Suzuki M, Tachibana I, Takeda Y, He P, Minami S, Iwasaki T, et al. Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation. J IMMUNOL. 2009;182(10):6485\u201393.","journal-title":"J IMMUNOL"},{"issue":"3","key":"4711_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","volume":"16","author":"JA Hellyer","year":"2021","unstructured":"Hellyer JA, Padda SK, Diehn M, Wakelee HA. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. J THORAC ONCOL. 2021;16(3):395\u2013403.","journal-title":"J THORAC ONCOL"},{"issue":"6","key":"4711_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1158\/0008-5472.CAN-22-1903","volume":"83","author":"L Guan","year":"2023","unstructured":"Guan L, Nambiar DK, Cao H, Viswanathan V, Kwok S, Hui AB, et al. NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells. CANCER RES. 2023;83(6):861\u201374.","journal-title":"CANCER RES"},{"key":"4711_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1746-1596-6-91","volume":"6","author":"L Jonsson","year":"2011","unstructured":"Jonsson L, Gaber A, Ulmert D, Uhlen M, Bjartell A, Jirstrom K. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. DIAGN PATHOL. 2011;6:91.","journal-title":"DIAGN PATHOL"},{"issue":"2","key":"4711_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41419-023-05627-0","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Lv C, Niu Y, Li C, Li X, Shang Y, et al. RBM3 suppresses stemness remodeling of prostate cancer in bone microenvironment by modulating N6-methyladenosine on CTNNB1 mRNA. CELL DEATH DIS. 2023;14(2):91.","journal-title":"CELL DEATH DIS"},{"key":"4711_CR33","doi-asserted-by":"crossref","unstructured":"Li K, Li S, Tang S, Zhang M, Ma Z, Wang Q et al. KIF22 promotes bladder cancer progression by activating the expression of CDCA3. INT J MOL MED. 2021; 48(6):211.","DOI":"10.3892\/ijmm.2021.5044"},{"issue":"1","key":"4711_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13046-022-02240-5","volume":"41","author":"Z Yang","year":"2022","unstructured":"Yang Z, Liang SQ, Zhao L, Yang H, Marti TM, Hegedus B, et al. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer. J EXP CLIN CANC RES. 2022;41(1):25.","journal-title":"J EXP CLIN CANC RES"},{"issue":"1","key":"4711_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s13046-019-1374-x","volume":"38","author":"Q Yang","year":"2019","unstructured":"Yang Q, Lang C, Wu Z, Dai Y, He S, Guo W, et al. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway. J EXP CLIN CANC RES. 2019;38(1):391.","journal-title":"J EXP CLIN CANC RES"},{"issue":"4","key":"4711_CR36","doi-asserted-by":"publisher","first-page":"e222010","DOI":"10.1148\/radiol.222010","volume":"307","author":"R Seifert","year":"2023","unstructured":"Seifert R, Rasul S, Seitzer K, Eveslage M, Rahbar NL, Kessel K, et al. A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. Radiology. 2023;307(4):e222010.","journal-title":"Radiology"},{"issue":"1","key":"4711_CR37","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1186\/s12967-023-04633-2","volume":"21","author":"W Zhu","year":"2023","unstructured":"Zhu W, Zeng H, Huang J, Wu J, Wang Y, Wang Z, et al. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer. J TRANSL MED. 2023;21(1):782.","journal-title":"J TRANSL MED"},{"issue":"11","key":"4711_CR38","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"Z Ma","year":"2022","unstructured":"Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R, et al. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. THERANOSTICS. 2022;12(11):4965\u201379.","journal-title":"THERANOSTICS"},{"key":"4711_CR39","doi-asserted-by":"publisher","first-page":"114392","DOI":"10.1016\/j.biopha.2023.114392","volume":"160","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, et al. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies. BIOMED PHARMACOTHER. 2023;160:114392.","journal-title":"BIOMED PHARMACOTHER"},{"issue":"3","key":"4711_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J CLIN ONCOL. 2015;33(3):272\u20137.","journal-title":"J CLIN ONCOL"},{"issue":"10","key":"4711_CR41","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J NATL COMPR CANC NE. 2023;21(10):1067\u201396.","journal-title":"J NATL COMPR CANC NE"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04711-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:31:43Z","timestamp":1775035903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04711-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4711"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04711-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"522"}}